U.S. looks to extradite Chinese researcher in GSK trade secrets case: Reuters

GlaxoSmithKline GSK House in Brentford, UK
Gongda Xue, who used to work at Friedrich Miescher Institute for Biomedical Research in Basel, is fighting extradition. (GlaxoSmithKline)

The U.S. wants Switzerland to hand over a Chinese scientist accused of helping his sister steal trade secrets from GlaxoSmithKline, Reuters reported on Monday. Gongda Xue allegedly received those secrets from his sister, conducted tests at his workplace in Basel and sent the results to associates in China. 

Swiss authorities arrested Xue in May and are keeping him in custody while they mull the extradition request, Reuters reported. He is fighting extradition and considered a potential flight risk, according to a Swiss Federal Criminal Court Verdict. 

Xue’s sister, Yu Xue, worked at GSK’s R&D unit in Pennsylvania from 2006 to 2016, when charges were brought and the Big Pharma fired her. She pleaded guilty last August to attempting to steal confidential research and funnel it to accomplices in China. 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Former GSK cancer scientist admits attempt to steal trade secrets 

Yu Xue sent her own research and that of other GSK scientists to her personal email address, as well as to associates who founded Nanjing, China-based Renopharma, the Department of Justice said in a statement at the time. She did so between Jan. 1, 2012 and Dec. 28, 2015, according to the complaint. 

The indictment, brought in January 2016, also implicated Yu Xue’s twin sister, Tian Xue, who was accused of hiding advances paid by Renopharma to Yu Xue. 

RELATED: GSK scientists accused of data theft in low-tech cybercrime case 

As for where their brother fits in, Gongda Xue allegedly received trade secrets from Yu Xue relating to “involved antibodies that bind to tumor cells and kill them,” Reuters reported. He performed tests at Friedrich Miescher Institute for Biomedical Research, where he worked until 2014, and then passed results on to conspirators in China. 

“Gongda Xue knowing received, bought, and possessed a trade secret belonging to GSK...knowing it to have been stolen...with the intent to convert that trade secret...to the economic benefit of someone other than GSK,” said one U.S. charge, according to Reuters. 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.